205 related articles for article (PubMed ID: 23740411)
1. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
Lyseng-Williamson KA
Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
[TBL] [Abstract][Full Text] [Related]
2. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
Kang C; Keam SJ; Shirley M; Syed YY
Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
4. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
Amon M; Busin M
Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
[TBL] [Abstract][Full Text] [Related]
5. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
Stewart R; Horwitz B; Howes J; Novack GD; Hart K
J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
[TBL] [Abstract][Full Text] [Related]
6. Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies.
Rajpal RK; Fong R; Comstock TL
Adv Ther; 2013 Oct; 30(10):907-23. PubMed ID: 24136301
[TBL] [Abstract][Full Text] [Related]
7. Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery.
Fong R; Silverstein BE; Peace JH; Williams JI; Vittitow JL
J Cataract Refract Surg; 2018 Oct; 44(10):1220-1229. PubMed ID: 30193927
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
Sheppard JD; Comstock TL; Cavet ME
Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
[TBL] [Abstract][Full Text] [Related]
9. Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.
Coffey MJ; Decory HH; Lane SS
Clin Ophthalmol; 2013; 7():299-312. PubMed ID: 23430378
[TBL] [Abstract][Full Text] [Related]
10. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
13. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
14. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
Schopf L; Enlow E; Popov A; Bourassa J; Chen H
Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
[TBL] [Abstract][Full Text] [Related]
15. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
[TBL] [Abstract][Full Text] [Related]
16. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
Noble S; Goa KL
BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
[TBL] [Abstract][Full Text] [Related]
17. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
18. Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery.
Pirouzian A; Craven ER
Clin Ophthalmol; 2014; 8():379-87. PubMed ID: 24550666
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
20. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain.
Salinger CL; Gaynes BI; Rajpal RK
Am J Manag Care; 2019 Jul; 25(12 Suppl):S215-S226. PubMed ID: 31419092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
